Multicenter retrospective cohort study reveals late-window endovascular treatment does not increase malignant cerebral edema risk in ischemic stroke, indicating broader treatment eligibility.
Accumulating evidence has demonstrated the feasibility and efficacy of endovascular treatment (EVT) in the late window (6–24 h). However, whether late-window EVT is associated with a higher risk of malignant cerebral edema (MCE) remains uncertain. Our aim is to assess whether late-window EVT is associated with MCE compared with early-window EVT (< 6 h). This multicenter, retrospective, cohort study analyzed data from four stroke centers. Patients receiving late-window EVT were matched 1:3 by age, sex, vascular risk factors, stroke etiology and previous drug use to early-window EVT. MCE was defined as a midline shift ≥ 5 mm on follow-up head CT within 72 h after EVT. Univariate and multivariate logistic regression was used to assess the association between time window and MCE. Among 480 patients (120 late-window, 360 early-window), the incidence of MCE was 24.2% in the late-window group and 21.4% in the controls ( P = 0.611). Onset-to-puncture time didn’t differ significantly between patients with and without MCE, poor outcome, mortality, END, or FR (all P > 0.05). Late-window EVT was not independently associated with MCE (OR = 1.028, P = 0.526), even after adjustment (OR = 1.072, P = 0.114). Findings were consistent across subgroups stratified by age, cardioembolism, NIHSS, and ASPECTS (all P > 0.05). Late-window EVT was not associated with a higher incidence of MCE or other adverse outcomes compared with early-window EVT. Concerns about MCE should not preclude acute ischemic stroke patients from receiving late-window EVT, providing evidence to support patient selection for EVT.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: